Adalvo to Join Forces with EQT for Next Growth Phase
Deal News | Jul 18, 2025 | PR Newswire Cision EQT
EQT X has announced the acquisition of a majority stake in Adalvo, a leading B2B dossier developer based in Malta, specializing in providing market-approval-ready generic drug dossiers to pharmaceutical companies. The acquisition highlights EQT's strategy of investing in companies that offer critical services to society, such as affordable healthcare. The platform offers dossiers that play a crucial role in enhancing access to generic drugs across various global markets. Existing shareholders, including Aztiq, will reinvest part of their holdings and remain minority shareholders. EQT plans to fund further R&D and operational excellence to support the next phase of Adalvo's growth, focusing on business development, supply chain expansion, and broader market reach. Established in 2018, Adalvo has partnered with over 170 generic companies across more than 140 countries, demonstrating its rapid growth within the pharmaceutical industry. The transaction is subject to customary conditions and is expected to close in the second half of 2025.
Sectors
- Pharmaceuticals
- Private Equity
Geography
- Malta – Adalvo is headquartered in Malta, making it a central geography for the company.
- Europe – Part of Adalvo's operational presence includes Europe, where it services a wide range of pharmaceutical markets.
- India – India is mentioned as one of the countries with an office, highlighting its strategic importance in Adalvo's operations.
- Sweden – Stockholm, Sweden, is the location stated for the announcement, indicating EQT's base of operations.
Industry
- Pharmaceuticals – The core business of Adalvo is within the pharmaceutical industry, specializing in developing dossiers for generic drugs.
- Private Equity – EQT X's acquisition of Adalvo represents private equity activity within the pharmaceutical sector.
Financials
- 55 - 60% – Percentage of EQT X's investment fund expected to be invested post the Adalvo acquisition, including closed and/or signed investments.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| EQT X | Acquiring Company | Company | EQT is a global private equity firm investing in companies that provide essential services to society. |
| Adalvo | Target Company | Company | A leading B2B dossier developer providing generic drug dossiers to pharmaceutical companies globally. |
| Aztiq | Selling/Existing Company | Company | The holding company of Adalvo's current Chairman Róbert Wessman, which will retain a minority share. |
| Róbert Wessman | Chairman, Existing Shareholder | Person | Chairman of Aztiq, current minority shareholder in Adalvo. |
| Matteo Thun | Partner at EQT | Person | Partner within EQT Private Capital's Advisory Team, speaking on the acquisition. |
| Anil Okay | CEO of Adalvo | Person | CEO who commented on the collaboration with EQT. |